Cognizant has been named a leader in business process services (BPS) for life sciences companies by consulting and research firm Everest Group.
Analyzing the market share, strengths and areas for improvement of 24 global service providers, Everest Group found that Cognizant stood out based on its investments in digital technologies and significant client base, with multi-year engagements.
Cognizant's service portfolio and cost-efficient, automation-driven capabilities in the pharmacovigilance segment were cited as examples of its value against competitors. Additionally, the report recognized Cognizant's acquisition of Zenith Technologies, which strengthened the company's IoT capabilities and demonstrated it as a leader in embedding advanced technology within operational platforms.
Cognizant's Shared Investigator Platform (SIP) was also recognized as an important asset to its business offerings. SIP launched in 2016 and is one of the first multi-tenant, single sign-on platforms enabling clinical trial information, operations, administrative documents and tasks to be shared across sponsors and their sites. While operational processes can account for 45% to 75% of the time and cost of clinical trials, the Cognizant-hosted platform's secure, common workspace for enhanced collaboration provides a faster, more cost-effective means to manage clinical trials among stakeholders.
Learn more about Cognizant Life Sciences Technology Solutions.
